Complete the Biologics License Application filing for AV7909
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 10 Jan 2022
- Due
- 31 Dec 2022
- Delivered
- April 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“completion of the Biologics License Application filing for AV7909, the Company's next generation anthrax vaccine candidate.”
What we found
Evidence strength A What the grades mean
The company completed the rolling submission of the Biologics License Application for AV7909 in April 2022, meeting the 2022 deadline.
-
A Emergent BioSolutions Inc. 10-K filed 2023-03-01
“In April 2022, we completed the rolling submission of a Biologics License Application ("BLA") filing with the FDA related to AV7909 and the application has been accepted for review.” ✓ confirmed on the page
Market reaction: the shares moved -7.8% against the S&P 500 over the three sessions around the disclosure (28 Feb 2023 to 3 Mar 2023). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory other
- Indicative materiality
- Medium rules
- Action
- Complete
- Deliverable
- Biologics License Application filing for AV7909
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Emergent BioSolutions Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-EBS-002473 · Corrections policy